modelA10BD11
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | MetforminAndLinagliptin | |
| ATC code: | A10BD11 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 63 | L |
| clearance: | 505 | mL/min |
| other parameters in model implementation | ||
Metformin and linagliptin is a fixed-dose oral antidiabetic combination therapy used in the management of type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that decreases hepatic glucose production and increases insulin sensitivity, while linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin release and suppress glucagon. This combination is approved for use in adults with type 2 diabetes.
Pharmacokinetics
Pharmacokinetic parameters summarized for healthy adult volunteers after oral administration of a fixed-dose combination tablet (metformin/linagliptin).
References
Pichereau, S, et al., & Friedrich, C (2015). Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects. International journal of clinical pharmacology and therapeutics 53(7) 582–592. DOI:10.5414/CP202237 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26073354
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)